European Journal of Surgical Oncology
Volume 36, Issue 3 , Pages 257-263 , March 2010

A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma

  • Z.-W. Peng

      Affiliations

    • Department of Hepatobiliary Surgery, Cancer Centre of Sun Yat-Sen University, 651 Dongfeng Road East, Guangzhou 510060, China
    • State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China
    • ,
  • M.-S. Chen

      Affiliations

    • Department of Hepatobiliary Surgery, Cancer Centre of Sun Yat-Sen University, 651 Dongfeng Road East, Guangzhou 510060, China
    • State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China
    • Corresponding Author InformationCorresponding author at: Department of Hepatobiliary Surgery, Cancer Centre of Sun Yat-Sen University, 651 Dongfeng Road East, Guangzhou 510060, PR China. Tel./fax: +86 20 8734 3117, +86 1390 224 1061 (mobile).
    • ,
  • H.-H. Liang

      Affiliations

    • Department of Hepatobiliary Surgery, Cancer Centre of Sun Yat-Sen University, 651 Dongfeng Road East, Guangzhou 510060, China
    • State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China
    • ,
  • H.-J. Gao

      Affiliations

    • Department of Hepatobiliary Surgery, Cancer Centre of Sun Yat-Sen University, 651 Dongfeng Road East, Guangzhou 510060, China
    • State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China
    • ,
  • Y.-J. Zhang

      Affiliations

    • Department of Hepatobiliary Surgery, Cancer Centre of Sun Yat-Sen University, 651 Dongfeng Road East, Guangzhou 510060, China
    • State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China
    • ,
  • J.-Q. Li

      Affiliations

    • Department of Hepatobiliary Surgery, Cancer Centre of Sun Yat-Sen University, 651 Dongfeng Road East, Guangzhou 510060, China
    • State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China
    • ,
  • Y.-Q. Zhang

      Affiliations

    • Department of Hepatobiliary Surgery, Cancer Centre of Sun Yat-Sen University, 651 Dongfeng Road East, Guangzhou 510060, China
    • State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China
    • ,
  • W.Y. Lau

      Affiliations

    • Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China

,Accepted 6 July 2009.

References 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108
  2. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979–94. Lancet. 1997;350:1142–1143
  3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745–750
  4. Bruix J, Sherman M. Practice guidelines committee, American association for the study of liver diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236
  5. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–1917
  6. Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg. 1995;221:291–298
  7. Schwartz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology. 2004;127:S268–S276
  8. Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005;234:961–967
  9. Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1,000 cases. Cancer. 2005;103:1201–1209
  10. Lau WY, Leung TW, Yu SC, Ho SK. Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg. 2003;237:171–179
  11. Curley SA. Radiofrequency ablation of malignant liver tumors. Oncologist. 2001;6:14–23
  12. Mulier S, Mulier P, Ni Y, et al. Complications of radiofrequency coagulation of liver tumors. Br J Surg. 2002;89:1206–1222
  13. Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243:321–328
  14. Livraghi T, Goldberg SN, Lazzaroni S, et al. Hepatocellular carcinoma: radiofrequency ablation of medium and large lesions. Radiology. 2000;214:761–768
  15. Zhang YJ, Liang HH, Chen MS, et al. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. Radiology. 2007;244:599–607
  16. Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol. 2006;16:661–669
  17. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–442
  18. Kwok PC, Lam TW, Chan SC, et al. A randomized clinical trial comparing autologous blood clot and gelfoam in transarterial chemoembolization for inoperable hepatocellular carcinoma. J Hepatol. 2000;32:955–964
  19. Peng ZW, Liang HH, Chen MS, et al. Percutaneous radiofrequency ablation for the treatment of hepatocellular carcinoma in the cardate lobe. Eur J Surg Oncol. 2008;34:166–172
  20. Chen MH, Yang W, Yan K, et al. Large liver tumors: protocol for radiofrequency ablation and its clinical application in 110 patients-mathematic model, overlapping mode, and electrode placement process. Radiology. 2004;232:260–271
  21. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona 2000 EASL Conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–430
  22. Development of ThermoDoxTM plus radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC). Celsion Corporation FDA Briefing Document 2006, IND number: 66,827, serial number: 027.
  23. Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg. 2005;242:158–171
  24. Lin SM, Lin CJ, Lin CC, et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma <or =4 cm. Gastroenterology. 2004;127:1714–1723
  25. Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005;129:122–130
  26. Livraghi T, Lazzaroni S, Meloni F. Radiofrequency ablation of hepatocellular carcinoma. Eur J Ultrasound. 2001;13:159–166
  27. Zhou XD, Tang ZY, Yang BH, et al. Experience of 1,000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer. 2001;91:1479–1486
  28. Goldberg SN, Hahn PF, Tanabe KK, et al. Percutaneous radiofrequency tissue ablation: does perfusion-mediated tissue cooling limit coagulation necrosis?. J Vasc Interv Radiol. 1998;9:101–111
  29. Seki T, Tamai T, Nakagawa T, et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma. Cancer. 2000;89:1245–1251
  30. Shi M, Zhang CQ, Zhang YQ, Liang XM, Li JQ. Micrometastasis of solitary hepatocellular carcinoma and appropriate resection margin. World J Surg. 2004;28:376–381

PII: S0748-7983(09)00230-3

doi: 10.1016/j.ejso.2009.07.007

European Journal of Surgical Oncology
Volume 36, Issue 3 , Pages 257-263 , March 2010

Article Tools

* Image Usage & Resolution